● Recruiting

Phase I Study to Evaluate KP405 in Healthy and Parkinson's Disease Patients

Condition: Safety Issues · Tolerance · Sponsor: Kariya Pharmaceuticals

PhaseEARLY_Phase 1

Planned participants88

Who can joinAll sexes, 18 Years to 80 Years

Healthy volunteersYes

About this study

This study will explore the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of KP405 as a potential new treatment for Parkinson's disease.

This description comes directly from the study's public registry record.

Talk to the study team

Ian Laquian, MBA · 5170029 · Ian.laquian@kariyapharma.com

Always discuss trial participation with your own doctor first.

Locations (1)

MAC

Manchester, United Kingdom

Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06189170